Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain
Condition(s):Hawthorn Red Combined Refractory Cancer PainLast Updated:September 30, 2022Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Hawthorn Red Combined Refractory Cancer PainLast Updated:September 30, 2022Not yet recruiting
Condition(s):Cancer PainLast Updated:January 17, 2024Not yet recruiting
Condition(s):Neoplasms; PainLast Updated:January 21, 2016Completed
Condition(s):Chronic Cancer PainLast Updated:April 26, 2017Completed
Condition(s):Cancer-Related PainLast Updated:June 22, 2020Completed
Condition(s):Gynecologic Cancer; Cancer Related Pain; Cancer Pain; AcupunctureLast Updated:January 29, 2024Completed
Condition(s):PainLast Updated:April 11, 2013Completed
Condition(s):Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naiveLast Updated:August 31, 2020Unknown status
Condition(s):Gynecologic Cancer; Cancer Related Pain; Cancer PainLast Updated:January 29, 2024Completed
Condition(s):Cancer PainLast Updated:August 23, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.